LUND, Sweden, Oct. 20, 2022 /PRNewswire/ -- According to the
instructions for the Nomination Committee of Immunovia AB (Publ)
that were adopted at the Annual General Meeting on
April 7, 2022, the Nomination
Committee shall consist of four members.
The Nomination Committee, which is to be appointed for the
period until a new Nomination Committee is appointed, shall
consist of four members, of which three will be appointed by the
Company's three largest shareholders in terms of voting, and the
fourth shall be the Chairman of the Board. In the event that
the Chairman of the Board is one of the three largest shareholders,
he shall, in his/her capacity as shareholder, make his seat
available and the next shareholder shall be offered the right
to appoint a member to the Nomination Committee.
The Chairman of the Board shall, as soon as reasonably
practicable after the end of the third quarter, contact the three
largest shareholders registered in the share register kept by
Euroclear Sweden AB at this time in an appropriate manner and
request them to, within a reasonable time, may not exceed 30 days,
in writing to the Nomination Committee name the person the
shareholder wishes to appoint as a member of the Nomination
Committee.
If one of the three largest shareholders do not wish
to exercise his right to appoint a member of the Nomination
Committee, the next shareholder shall in turn be offered the
right to appoint a member of the Nomination Committee. In the event
that several shareholders waive their right to appoint members
of the Nomination Committee, the Chairman of the Board shall
not have to contact more than eight shareholders, unless it is
necessary to convene a Nomination Committee consisting of at
least three members.
Unless otherwise agreed between the members, the member
appointed by the largest shareholder in terms of number of
votes shall be appointed chairman of the nomination committee.
The Chairman of the Board or another Board member shall never
be the Chairman of the Nomination Committee.
Based on the above, the Nomination Committee for the 2023 Annual
General Meeting has been determined to consist of the
following persons who together represent 13.46 percent of the
number of shares and votes in the company as of September 30, 2022:
- Ranny Davidoff, representing Ranny Davidoff
- Carl Borrebaeck, Chairman of the Board
- Peter Lindvall representing Mikael Löfman; and
- Mats Leifland, representing Mats
Ohlin
The Nomination Committee's proposal will be presented in the
notice convening the Annual General Meeting 2023 and at the
company's website, www.immunovia.com.
Shareholders who wish to submit proposals to the Nomination
Committee are welcome to contact the Nomination Committee at
the company's address. In order for the Nomination Committee to
be able to consider a proposal, the proposal must have been
received in good time before the Annual General Meeting, but
no later than January 31,
2023.
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
The information was submitted for publication, through the
agency of the contact person set out above, at 08.30 am
CET on October 20, 2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit https://immunovia.com/
The following files are available for download:
https://mb.cision.com/Main/13121/3651442/1640913.pdf
|
Press Release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/nomination-committee-appointed-for-the-2023-annual-general-meeting-of-immunovia-ab-publ-301654526.html